nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.06.2019 | Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

The Role of KIT Mutations in Anaphylaxis

verfasst von: Elise Coulson, Sherry Zhou, Cem Akin

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Gain of function KIT mutations are detected in clonal mast cell diseases, namely mastocytosis and monoclonal mast cell activation syndrome. Timely diagnosis and treatment of these disorders are crucial because of their association with severe and life-threatening anaphylaxis. KIT mutations also have implications for targeted therapies of mast cell disorders. This review article strives to serve as an overview of the role of clonal mast cell disorders in anaphylaxis while elucidating current and future therapies.

Recent Findings

Clonal mast cell disease has been increasingly diagnosed in patients with severe hymenoptera allergy and those with recurrent unexplained anaphylaxis. The current state of knowledge of the epidemiology, pathophysiology, diagnosis, and treatment of mastocytosis with a particular focus on anaphylaxis and its triggers which are described in this context. Novel and forthcoming treatments are discussed including the relevance of KIT mutation status.

Summary

This review provides an overview of the role of KIT mutations in mastocytosis and anaphylaxis, and highlights emerging therapies for mastocytosis, targeting these mutations.

Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7. https://doi.org/10.1016/j.jaci.2005.12.1303.CrossRefPubMed

Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):442–77. https://doi.org/10.1016/j.jaci.2010.06.022.CrossRef

Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol. 2002;110(3):341–8.CrossRef

Wood RA, Camargo CAJ, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7. https://doi.org/10.1016/j.jaci.2013.08.016.CrossRefPubMed

Poulos LM, Waters A-M, Correll PK, Loblay RH, Marks GB. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol. 2007;120(4):878–84. https://doi.org/10.1016/j.jaci.2007.07.040.CrossRefPubMed

Lieberman P, Camargo CAJ, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97(5):596–602. https://doi.org/10.1016/S1081-1206(10)61086-1.CrossRefPubMed

Sicherer SH, Muñoz-Furlong A, Burks AW, Sampson HA. Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey. J Allergy Clin Immunol. 1999. https://doi.org/10.1016/S0091-6749(99)70224-1.CrossRef

Lieberman P. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8(4):316–20. https://doi.org/10.1097/ACI.0b013e3283036a69.CrossRefPubMed

Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo CAJ. Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. J Allergy Clin Immunol Pract. 2014;2(1):46–51. https://doi.org/10.1016/j.jaip.2013.08.012.CrossRefPubMed

10.

Alvarez-Perea A, Ameiro B, Morales C, et al. Anaphylaxis in the pediatric emergency department: analysis of 133 cases after an allergy workup. J Allergy Clin Immunol Pract. 2017;5(5):1256–63. https://doi.org/10.1016/j.jaip.2017.02.011.CrossRefPubMed

11.

Khan BQ, Kemp SF. Pathophysiology of anaphylaxis. Curr Opin Allergy Clin Immunol. 2011;11(4):319–25. https://doi.org/10.1097/ACI.0b013e3283481ab6.CrossRefPubMed

12.

Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704. https://doi.org/10.1038/nm.2755.CrossRefPubMedPubMedCentral

13.

Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–48. https://doi.org/10.1016/j.jaci.2017.06.003.CrossRefPubMedPubMedCentral

14.

Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol. 1981;68(5):365–71.CrossRef

15.

Golden DBK, Tracy JM, Freeman TM, Hoffman DR. Negative venom skin test results in patients with histories of systemic reaction to a sting. J Allergy Clin Immunol. 2003;112(3):495–8.CrossRef

16.

Simons FER, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2–24. https://doi.org/10.1016/j.jaci.2007.05.001.CrossRefPubMed

17.

Bryce PJ, Falahati R, Kenney LL, et al. Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis. J Allergy Clin Immunol. 2016;138(3):769–79. https://doi.org/10.1016/j.jaci.2016.01.049.CrossRefPubMedPubMedCentral

18.

Buka RJ, Crossman RJ, Melchior CL, et al. Anaphylaxis and ethnicity: higher incidence in British South Asians. Allergy. 2015;70(12):1580–7. https://doi.org/10.1111/all.12702.CrossRefPubMed

19.

• Volertas S, Schuler CF 4th, Akin C. New insights into clonal mast cell disorders including mastocytosis. Immunol Allergy Clin N Am. 2018;38(3):341–50. https://doi.org/10.1016/j.iac.2018.04.014 Good overview of mastocytosis. CrossRef

20.

Valent P. Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res. 2013;3(2):159–72.PubMedPubMedCentral

21.

Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: a nationwide population-based study. Am J Hematol. 2016;91(11):1069–75. https://doi.org/10.1002/ajh.24490.CrossRefPubMed

22.

• Worm M, Francuzik W, Renaudin J-M, et al. Factors increasing the risk for a severe reaction in anaphylaxis: an analysis of data from The European Anaphylaxis Registry. Allergy. 2018;73(6):1322–30. https://doi.org/10.1111/all.13380 Shows increase risk of anaphylaxis in patients with mastocytosis. CrossRefPubMed

23.

•• Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420–7. https://doi.org/10.1182/blood-2016-09-731893 Describes the current classification and emerging treatments of mastocytosis. CrossRefPubMedPubMedCentral

24.

Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96(3):2S–4S.CrossRef

25.

Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140(2):349–55. https://doi.org/10.1016/j.jaci.2017.06.007.CrossRefPubMed

26.

Bibi S, Arock M. Tyrosine kinase inhibition in mastocytosis: KIT and beyond KIT. Immunol Allergy Clin North Am 2018;38(3):527–543. https://doi.org/10.1016/j.iac.2018.04.007.CrossRef

27.

Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6(11):3341–51.CrossRef

28.

Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood. 2008;112(6):2463–73. https://doi.org/10.1182/blood-2007-09-115477.CrossRefPubMedPubMedCentral

29.

Komi DEA, Rambasek T, Wohrl S. Mastocytosis: from a molecular point of view. Clin Rev Allergy Immunol. 2018;54(3):397–411. https://doi.org/10.1007/s12016-017-8619-2.CrossRefPubMed

30.

Akin C. Anaphylaxis and mast cell disease: what is the risk? Curr Allergy Asthma Rep. 2010;10(1):34–8. https://doi.org/10.1007/s11882-009-0080-8.CrossRefPubMed

31.

Cruse G, Metcalfe DD, Olivera A. Functional deregulation of KIT: Link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am 2014. https://doi.org/10.1016/j.iac.2014.01.002.CrossRef

32.

Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011;13(2):180–8. https://doi.org/10.1016/j.jmoldx.2010.10.004.CrossRefPubMedPubMedCentral

33.

Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 2007. https://doi.org/10.1111/j.1365-2141.2007.06619.x.CrossRef

34.

Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015. https://doi.org/10.1038/leu.2015.24.CrossRef

35.

Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63(2):226–32. https://doi.org/10.1111/j.1398-9995.2007.01569.x.CrossRefPubMed

36.

Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37(10):1547–1555. https://doi.org/10.1111/j.1365-2222.2007.02804.x.CrossRef

37.

Gulen T, Hagglund H, Dahlen B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy. 2014;44(1):121–9. https://doi.org/10.1111/cea.12225.CrossRefPubMed

38.

Nwaru BI, Dhami S, Sheikh A. Idiopathic anaphylaxis. Curr Treat options allergy. 2017;4(3):312–9. https://doi.org/10.1007/s40521-017-0136-2.CrossRefPubMedPubMedCentral

39.

Ahanchian H, Behmanesh F, Azad FJ, et al. A survey of anaphylaxis etiology and treatment. Med Gas Res. 2018;8(4):129–34. https://doi.org/10.4103/2045-9912.248262.CrossRefPubMed

40.

• Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood. 2007;110(7):2331–3. https://doi.org/10.1182/blood-2006-06-028100 First demonstration of clonal mast cell disease with KIT mutations in patients formerly diagnosed with idiopathic anaphylaxis. CrossRefPubMedPubMedCentral

41.

Carter MC, Desai A, Komarow HD, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol. 2018;141(1):180–188.e3. https://doi.org/10.1016/j.jaci.2017.05.036.CrossRefPubMed

42.

Niedoszytko M, De Monchy J, Van Doormaal JJ, Jassem E, Oude Elberink JNG. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy Eur J Allergy Clin Immunol. 2009. https://doi.org/10.1111/j.1398-9995.2009.02118.x.CrossRef

43.

Haeberli G, Brönnimann M, Hunziker T, Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003. https://doi.org/10.1046/j.1365-2222.2003.01755.x.

44.

Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol. 2009. https://doi.org/10.1016/j.jaci.2009.08.027.CrossRef

45.

Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009. https://doi.org/10.1016/j.jaci.2008.11.018.CrossRef

46.

Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol. 2012. https://doi.org/10.1016/j.jaci.2012.03.024.CrossRef

47.

• Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010;125(6):1269--1278.e2. https://doi.org/10.1016/j.jaci.2010.02.019 . Guidance on when to suspect clonal mast cell disease in anaphylaxis. CrossRef

48.

Haeberli G, Bronnimann M, Hunziker T, Muller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy. 2003;33(9):1216–20.CrossRef

49.

Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol. 2008;121(1):256–7. https://doi.org/10.1016/j.jaci.2007.10.014.CrossRefPubMed

50.

Bonadonna P, Gonzalez-de-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1(5):474–8. https://doi.org/10.1016/j.jaip.2013.06.014.CrossRefPubMed

51.

Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2(3):266–70. https://doi.org/10.1016/j.jaip.2014.03.009.CrossRefPubMed

52.

da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Pract. 2013;1(6):687–8. https://doi.org/10.1016/j.jaip.2013.07.004.CrossRefPubMed

53.

Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy. 2009;64(9):1379–82. https://doi.org/10.1111/j.1398-9995.2009.02108.x.CrossRefPubMed

54.

Guyer AC, Saff RR, Conroy M, et al. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract. 2015. https://doi.org/10.1016/j.jaip.2014.11.011.CrossRef

55.

• Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2019; Provides an excellent summary of adverse drug reactions in patients with mastocytosis.

56.

Marone G, Stellato C. Activation of human mast cells and basophils by general anaesthetic drugs. Monogr Allergy. 1992;30:54–73.PubMed

57.

Genovese A, Stellato C, Marsella CV, Adt M, Marone G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int Arch Allergy Immunol. 1996;110(1):13–22. https://doi.org/10.1159/000237305.CrossRefPubMed

58.

Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120(3):753–9. https://doi.org/10.1097/ALN.0000000000000031.CrossRefPubMed

59.

Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. December 2018. https://doi.org/10.1016/j.jaci.2018.10.063.CrossRef

60.

Bridgman DE, Clarke R, Sadleir PHM, Stedmon JJ, Platt P. Systemic mastocytosis presenting as intraoperative anaphylaxis with atypical features: a report of two cases. Anaesth Intensive Care. 2013;41(1):116–21.CrossRef

61.

Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish network on mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol. 2015;167(1):47–56. https://doi.org/10.1159/000436969.CrossRefPubMed

62.

Vaughan ST, Jones GN. Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesia. Anaesthesia. 1998;53(8):804–7.CrossRef

63.

Ten Hagen A, Doldersum P, van Raaij T. Anaphylactic shock during cement implantation of a total hip arthroplasty in a patient with underlying mastocytosis: case report of a rare intraoperative complication. Patient Saf Surg. 2016;10:25. https://doi.org/10.1186/s13037-016-0113-x.CrossRefPubMedPubMedCentral

64.

Ishii K, Miyoshi H, Akiyama D, et al. Anesthetic management of patients with systemic mastocytosis. J Clin Anesth. 2018;50:61. https://doi.org/10.1016/j.jclinane.2018.06.047.CrossRefPubMed

65.

Hermans MAW, Arends NJT, Gerth van Wijk R, et al. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol 2017;119(4):304–309. https://doi.org/10.1016/j.anai.2017.07.022.CrossRef

66.

Prieto-Garcia A, Alvarez-Perea A, Matito A, et al. Systemic mastocytosis presenting as IgE-mediated food-induced anaphylaxis: a report of two cases. J Allergy Clin Immunol Pract. 2015;3(3):456–8. https://doi.org/10.1016/j.jaip.2015.01.011.CrossRefPubMed

67.

Commins SP, Satinover SM, Hosen J, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009;123(2):426–33. https://doi.org/10.1016/j.jaci.2008.10.052.CrossRefPubMed

68.

Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2011;127(5):1286–93.e6. https://doi.org/10.1016/j.jaci.2011.02.019.CrossRefPubMedPubMedCentral

69.

Roenneberg S, Böhner A, Brockow K, et al. α-Gal-a new clue for anaphylaxis in mastocytosis. J Allergy Clin Immunol Pract. 2016. https://doi.org/10.1016/j.jaip.2015.11.027.CrossRef

70.

Carter MC, Ruiz-Esteves KN, Workman L, Lieberman P, Platts-Mills TAE, Metcalfe DD. Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis. Allergy Eur J Allergy Clin Immunol. 2018. https://doi.org/10.1111/all.13366.CrossRef

71.

van Nunen S. Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance. Asia Pac Allergy. 2015;5(1):3–16. https://doi.org/10.5415/apallergy.2015.5.1.3.CrossRefPubMedPubMedCentral

72.

Romano A, Di Fonso M, Giuffreda F, et al. Food-dependent exercise-induced anaphylaxis: clinical and laboratory findings in 54 subjects. Int Arch Allergy Immunol. 2001;125(3):264–72. https://doi.org/10.1159/000053825.CrossRefPubMed

73.

Hanakawa Y, Tohyama M, Shirakata Y, Murakami S, Hashimoto K. Food-dependent exercise-induced anaphylaxis: a case related to the amount of food allergen ingested. Br J Dermatol. 1998;138(5):898–900.CrossRef

74.

Alfaya Arias T, Soriano Gomis V, Soto Mera T, et al. Key issues in Hymenoptera venom allergy: an update. J Investig Allergol Clin Immunol. 2017;27(1):19–31. https://doi.org/10.18176/jiaci.0123.CrossRefPubMed

75.

Alvarez-Twose I, González-De-Olano D, Sánchez-Munoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012. https://doi.org/10.1159/000329856.CrossRef

76.

Alvarez-Twose I, Gonzalez-de-Olano D, Sanchez-Munoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157(3):275–80. https://doi.org/10.1159/000329856.CrossRefPubMed

77.

Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 2017;140(2):321–33. https://doi.org/10.1016/j.jaci.2017.06.012.CrossRefPubMed

78.

Mullol J, Bousquet J, Bachert C, et al. Update on rupatadine in the management of allergic disorders. Allergy. 2015;(70 Suppl):1:1–24. https://doi.org/10.1111/all.12531.CrossRef

79.

Kettelhut BV, Berkebile C, Bradley D, Metcalfe DD. A double-blind, placebo-controlled, crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis. J Allergy Clin Immunol. 1989;83(5):866–70.CrossRef

80.

Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets. 2006;5(1):61–77.CrossRef

81.

Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol. 2012;29(2):222–3. https://doi.org/10.1111/j.1525-1470.2011.01576.x.CrossRefPubMed

82.

Tolar J, Tope WD, Neglia JP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med. 2004;350(7):735–6. https://doi.org/10.1056/NEJM200402123500723.CrossRefPubMed

83.

Barete S, Lortholary O, Damaj G, et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood. 2015;126(8):1009--1016; quiz 1050. https://doi.org/10.1182/blood-2014-12-614743.CrossRef

84.

Ustun C, Gotlib J, Popat U, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant. 2016. https://doi.org/10.1016/j.bbmt.2016.04.018.CrossRef

85.

Kasamon YL, Ko C-W, Subramaniam S, et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. Oncologist. 2018;23(12):1511–9. https://doi.org/10.1634/theoncologist.2018-0222.CrossRefPubMed

86.

•• Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 2016;374(26):2530–2541. https://doi.org/10.1056/NEJMoa1513098 . Multicenter study of multitargeted tyrosine kinase inhibitor midostaurin in advanced mastocytosis, which led to FDA approval of the drug for advanced mastocytosis. CrossRef

87.

DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470–8. https://doi.org/10.1038/leu.2017.234.CrossRefPubMed

88.

van Anrooij B, Oude Elberink JNG, Span LFR, et al. Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial. J Allergy Clin Immunol. 2018;142(3):1006–1008.e7. https://doi.org/10.1016/j.jaci.2018.06.003.CrossRefPubMed

89.

Evans E, Gardino A, Hodous B, et al. Blu-285, a potent and selective inhibitor for hematologic malignancies with KIT exon 17 mutations. Blood. 2015.

90.

Drummond MW, DeAngelo DJ, Deininger MW, et al. Preliminary safety and clinical activity in a phase 1 study of Blu- 285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Blood Conf 58th Annu Meet Am Soc Hematol ASH 2016 United States Conf start 20161203 Conf end 20161206. 2016.

91.

Hinojosa T, Lewis DJ, Vangipuram R, et al. The efficacy of omalizumab in cutaneous mastocytosis: a case series. Dermatol Ther. January 2019:e12848. https://doi.org/10.1111/dth.12848.

92.

Peterson MR, Coop CA. Long-term omalizumab use in the treatment of exercise-induced anaphylaxis. Allergy Rhinol (Providence). 2017;8(3):170–2. https://doi.org/10.2500/ar.2017.8.0204.CrossRef

93.

•• Broesby-Olsen S, Vestergaard H, Mortz CG, et al. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy. 2018;73(1):230–8. https://doi.org/10.1111/all.13237 Showed omalizumab effectivley decreased episodes of anaphylaxis and improved symptoms in patients with SM. CrossRefPubMed

Titel: The Role of KIT Mutations in Anaphylaxis
verfasst von: Elise Coulson
Sherry Zhou
Cem Akin
Publikationsdatum: 01.06.2019
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 6/2019
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-019-0863-5

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

The Role of KIT Mutations in Anaphylaxis

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO